JP2013538863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538863A5 JP2013538863A5 JP2013532104A JP2013532104A JP2013538863A5 JP 2013538863 A5 JP2013538863 A5 JP 2013538863A5 JP 2013532104 A JP2013532104 A JP 2013532104A JP 2013532104 A JP2013532104 A JP 2013532104A JP 2013538863 A5 JP2013538863 A5 JP 2013538863A5
- Authority
- JP
- Japan
- Prior art keywords
- fii
- fibrinogen
- fviia
- medicament according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 28
- 108010049003 Fibrinogen Proteins 0.000 claims 16
- 102000008946 Fibrinogen Human genes 0.000 claims 16
- 229940012952 fibrinogen Drugs 0.000 claims 16
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 14
- 239000003114 blood coagulation factor Substances 0.000 claims 14
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 206010053567 Coagulopathies Diseases 0.000 claims 5
- 208000024659 Hemostatic disease Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 208000034158 bleeding Diseases 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 230000009852 coagulant defect Effects 0.000 claims 3
- 208000012908 vascular hemostatic disease Diseases 0.000 claims 3
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims 2
- 230000023597 hemostasis Effects 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101001052793 Homo sapiens GDP-L-fucose synthase Proteins 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 102000050085 human TSTA3 Human genes 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39022410P | 2010-10-06 | 2010-10-06 | |
| US61/390,224 | 2010-10-06 | ||
| PCT/EP2011/066241 WO2012045569A1 (en) | 2010-10-06 | 2011-09-19 | Factor ii and fibrinogen for treatment of haemostatic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538863A JP2013538863A (ja) | 2013-10-17 |
| JP2013538863A5 true JP2013538863A5 (enExample) | 2014-11-20 |
| JP6000259B2 JP6000259B2 (ja) | 2016-09-28 |
Family
ID=44677879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532104A Expired - Fee Related JP6000259B2 (ja) | 2010-10-06 | 2011-09-19 | 止血障害治療用第ｉｉ因子およびフィブリノーゲン |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9433664B2 (enExample) |
| EP (1) | EP2624859B1 (enExample) |
| JP (1) | JP6000259B2 (enExample) |
| KR (1) | KR20130136988A (enExample) |
| CN (1) | CN103221061A (enExample) |
| AU (1) | AU2011313505B2 (enExample) |
| BR (1) | BR112013008034A2 (enExample) |
| CA (1) | CA2812888A1 (enExample) |
| DK (1) | DK2624859T3 (enExample) |
| ES (1) | ES2625153T3 (enExample) |
| HU (1) | HUE033204T2 (enExample) |
| MX (1) | MX343784B (enExample) |
| PL (1) | PL2624859T3 (enExample) |
| RU (1) | RU2606155C2 (enExample) |
| SG (2) | SG10201508159SA (enExample) |
| WO (1) | WO2012045569A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12171463B2 (en) | 2008-10-03 | 2024-12-24 | Femasys Inc. | Contrast agent generation and injection system for sonographic imaging |
| SG10201508159SA (en) | 2010-10-06 | 2015-10-29 | Medimmune Ltd | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
| IL230150A0 (en) * | 2013-12-24 | 2014-09-30 | Omrix Biopharmaceuticals Ltd | One-component fibrin glue containing zymogens |
| JP7227905B2 (ja) | 2017-02-09 | 2023-02-22 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血の処置または予防における使用のための血液凝固因子代替製品 |
| CN116059431A (zh) * | 2021-10-29 | 2023-05-05 | 丁琴琴 | 一种含凝血因子的双层止血敷料及其制备方法 |
| WO2023220412A1 (en) * | 2022-05-13 | 2023-11-16 | Cedars-Sinai Medical Center | Hemostatic monitor |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3165600D1 (en) | 1980-01-28 | 1984-09-27 | Baxter Travenol Lab | Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions |
| US4501731A (en) | 1983-06-27 | 1985-02-26 | Tishkoff Garson H | Treatment of disparate bleeding disorders with factor X zymogen |
| DE4430204A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
| HUP9700603A3 (en) | 1996-03-20 | 2001-08-28 | Baxter Ag | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| US7094428B2 (en) | 2000-06-16 | 2006-08-22 | The University Of Medicine And Dentistry Of New Jersey | Hemostatic compositions, devices and methods |
| US6825323B2 (en) | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
| ATE386538T1 (de) | 2001-02-05 | 2008-03-15 | Novo Nordisk Healthcare Ag | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden |
| US20060025336A1 (en) | 2001-07-16 | 2006-02-02 | Novo Nordisk A/S | Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides |
| AU2002354846B2 (en) | 2001-07-20 | 2007-08-02 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| US20040101546A1 (en) * | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
| EP1587424A4 (en) | 2002-12-31 | 2012-01-25 | Marinepolymer Tech Inc | Bleeding Compounds and their uses |
| GB0324044D0 (en) | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| EP1748781B1 (en) | 2004-05-27 | 2012-12-19 | Baxter International Inc. | Methods for treating bleeding disorders using sulfated polysaccharides |
| EP1893230A2 (en) | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| MX2008006313A (es) | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| CA2644926A1 (en) * | 2006-03-06 | 2007-09-13 | Humagene, Inc. | A method for the preparation of recombinant human thrombin and fibrinogen |
| US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
| WO2008051513A2 (en) | 2006-10-23 | 2008-05-02 | Allan Pronovost | Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding |
| EP1935429A1 (en) | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates |
| US20080267940A1 (en) | 2007-03-30 | 2008-10-30 | Mohammed Syed F | Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue |
| NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
| US8852558B2 (en) | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
| EP2337793A4 (en) | 2008-10-08 | 2013-04-10 | Thrombodyne Inc | METHOD FOR PRODUCING CONCENTRATED FIBRINOGEN AND PLAIN-CONTAINING COMPOSITIONS |
| SG10201508159SA (en) | 2010-10-06 | 2015-10-29 | Medimmune Ltd | Factor II And Fibrinogen For Treatment Of Haemostatic Disorders |
-
2011
- 2011-09-19 SG SG10201508159SA patent/SG10201508159SA/en unknown
- 2011-09-19 SG SG2013021498A patent/SG188639A1/en unknown
- 2011-09-19 ES ES11761051.9T patent/ES2625153T3/es active Active
- 2011-09-19 BR BR112013008034A patent/BR112013008034A2/pt not_active IP Right Cessation
- 2011-09-19 EP EP11761051.9A patent/EP2624859B1/en not_active Revoked
- 2011-09-19 JP JP2013532104A patent/JP6000259B2/ja not_active Expired - Fee Related
- 2011-09-19 KR KR1020137008520A patent/KR20130136988A/ko not_active Ceased
- 2011-09-19 RU RU2013120033A patent/RU2606155C2/ru not_active IP Right Cessation
- 2011-09-19 PL PL11761051T patent/PL2624859T3/pl unknown
- 2011-09-19 DK DK11761051.9T patent/DK2624859T3/en active
- 2011-09-19 US US13/877,854 patent/US9433664B2/en not_active Expired - Fee Related
- 2011-09-19 CA CA2812888A patent/CA2812888A1/en not_active Abandoned
- 2011-09-19 HU HUE11761051A patent/HUE033204T2/en unknown
- 2011-09-19 WO PCT/EP2011/066241 patent/WO2012045569A1/en not_active Ceased
- 2011-09-19 CN CN2011800479754A patent/CN103221061A/zh active Pending
- 2011-09-19 AU AU2011313505A patent/AU2011313505B2/en not_active Ceased
- 2011-09-19 MX MX2013003715A patent/MX343784B/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Camm et al. | Edoxaban: a new oral direct factor xa inhibitor | |
| Abshire et al. | Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors | |
| Reed et al. | Uses of tranexamic acid | |
| JP2013538863A5 (enExample) | ||
| Beikaei et al. | Evaluating the effect of intravenous tranexamic acid on intraoperative bleeding during elective rhinoplasty surgery | |
| WO2015066700A3 (en) | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation | |
| US20250099466A1 (en) | Milvexian for prevention and treatment of thromboembolic disorders | |
| Miesbach et al. | Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study | |
| Thipparampall et al. | The effect of different dose regimens of tranexamic acid in reducing blood loss during hip surgery | |
| Kawano et al. | Use of rivaroxaban for the effective management of disseminated intravascular coagulation associated with abdominal aortic aneurysm | |
| JP2014529606A5 (enExample) | ||
| Tendera et al. | ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation? | |
| Mauser‐Bunschoten et al. | Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors | |
| Filsoufi et al. | Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII | |
| Sannino et al. | Postoperative bleeding in patients taking oral anticoagulation therapy after “All-on-four” rehabilitation: A case-control study | |
| Yang et al. | Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage | |
| Ashikhmina et al. | Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest | |
| RU2013120033A (ru) | Фактор ii и фибриноген для лечения гемостатических нарушений | |
| Awad et al. | Dabigatran, intracranial hemorrhage, and the neurosurgeon | |
| Spira et al. | Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A | |
| Diener | Pro:“The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.” | |
| McBeth et al. | A surgeon's guide to anticoagulant and antiplatelet medications part one: warfarin and new direct oral anticoagulant medications | |
| Berndtson et al. | The epidemic of pre-injury oral antiplatelet and anticoagulant use | |
| Hacihanefioglu et al. | Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard–Soulier syndrome | |
| Nardetto et al. | Intravenous thrombolysis for acute stroke in a patient on treatment with rivaroxaban |